🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Albert David Limited ALBERTDAVD NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.albertdavidindia.com
Company Profile ↓
₹860.25
+8.20% 1Y
Mkt Cap₹490.96 Cr
P/E-328.34
P/B1.20
Div. Yield0.68%
52W High₹898.60
52W Low₹582.79
Book Value₹686.04
EPS (TTM)₹-2.62

Company Overview

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, and vision care products. The company exports its products to Latin American, South East Asian and North African countries Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.08.

Recent Developments

  • Mar 2026 Revenue of ₹329.36 Cr (-4.0% YoY); net profit ₹-1.49 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -4.0%, earnings -108.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.1%, profit CAGR -34.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.05%
1 Year:-4.04%

Compounded Profit Growth

5 Years:-34.71%
1 Year:-108.69%

Stock Price Performance

1 Year:+8.20%
6 Months:+27.14%
3 Months:+24.48%
1 Month:+17.75%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
₹582.79 ₹898.60
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.24 · Neutral
Price Performance
1M+17.75%
3M+24.48%
6M+27.14%
1Y+8.20%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -1.1% CAGR over 5 years.
  • Earnings shrank at -34.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-328.34
Industry PE
41.64
Forward P/E
-
PEG Ratio
-
Book Value
₹686.04
Price to Book
1.20
P/S
1.27
EV/EBITDA
34.97
Dividend Yield
0.68%

Growth (CAGR)

Revenue 5Y
-1.05%
Profit 5Y
-34.71%
Revenue (YoY)
-4.04%
Earnings (YoY)
-108.69%

Profitability & Returns

ROCE
0.76%
ROE
-0.38%
ROA
-0.29%
Profit Margin
-0.45%
Op Margin
0.04%
Gross Margin
64.83%
EPS (Latest Qtr)
₹-37.56
EPS (TTM)
₹-2.62

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
2.74
Current Ratio
3.24
Debt
₹29.58 Cr
Total Assets
₹519.13 Cr
Current Assets
₹374.40 Cr
Working Capital
₹258.97 Cr

Ownership

Promoter Holding
64.04%
Chg in Prom Hold
-0.00%
FII / Inst Holding
1.61%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹490.96 Cr
Total Revenue (TTM)
₹329.36 Cr
EBITDA
₹12.83 Cr
Free Cash Flow
₹-36.77 Cr
Operating Cash Flow
₹-7.66 Cr
Shares Outstanding
₹57.07 L
Gross Margin
64.83%
Payout Ratio
29.69%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALBERTDAVD Albert David Limited NSEPHARMA 860.25 -328.34 ₹490.96 Cr 0.68% 0.76% -0.38% -1.05% -34.71%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -74.89 Cr70.57 Cr87.24 Cr89.93 Cr85.86 Cr
Cost of Revenue -29.33 Cr25.28 Cr30.65 Cr27.83 Cr30.10 Cr
Gross Profit -45.57 Cr45.29 Cr56.59 Cr62.09 Cr55.77 Cr
Operating Expenses -52.13 Cr58.33 Cr56.28 Cr53.69 Cr55.73 Cr
Operating Income --6.56 Cr-13.04 Cr31.24 L8.40 Cr3.37 L
EBITDA --9.86 Cr11.38 Cr39.68 L23.22 Cr-22.08 Cr
Interest Expense -13.15 L55.48 L75.07 L89.77 L42.91 L
Pretax Income --11.81 Cr8.44 Cr-2.58 Cr19.90 Cr-25.23 Cr
Tax Provision --1.48 Cr50.07 L71.96 L4.60 Cr-3.80 Cr
Net Income --10.33 Cr7.94 Cr-3.30 Cr15.30 Cr-21.43 Cr
Diluted EPS --18.1013.91-5.7926.81-37.56

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -340.01 Cr360.26 Cr343.25 Cr329.36 Cr
Cost of Revenue -125.68 Cr128.40 Cr118.28 Cr115.84 Cr
Gross Profit -214.33 Cr231.86 Cr224.96 Cr213.53 Cr
Operating Expenses -177.78 Cr190.81 Cr227.77 Cr213.40 Cr
Operating Income -36.54 Cr41.05 Cr-2.81 Cr12.85 L
EBITDA -59.62 Cr104.32 Cr32.49 Cr12.83 Cr
Interest Expense -34.00 L20.72 L29.64 L2.55 Cr
Pretax Income -50.74 Cr97.29 Cr25.23 Cr52.49 L
Tax Provision -14.56 Cr21.87 Cr8.03 Cr2.02 Cr
Net Income -36.17 Cr75.42 Cr17.20 Cr-1.49 Cr
Diluted EPS -63.39132.1530.14-2.62

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -423.39 Cr497.99 Cr511.42 Cr519.13 Cr
Current Assets -304.24 Cr371.63 Cr354.05 Cr374.40 Cr
Cash & Equivalents -1.45 Cr5.44 Cr41.73 L29.91 L
Inventory -50.68 Cr43.61 Cr63.90 Cr58.27 Cr
Receivables -30.33 Cr29.33 Cr27.37 Cr33.92 Cr
Total Liabilities -111.82 Cr115.01 Cr118.93 Cr127.60 Cr
Current Liabilities -98.94 Cr99.05 Cr104.18 Cr115.43 Cr
Long Term Debt -----
Total Debt -5.32 Cr3.32 Cr12.32 Cr29.58 Cr
Total Equity -311.57 Cr382.98 Cr392.48 Cr391.54 Cr
Shares Outstanding -57.07 L57.07 L57.07 L57.07 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -10.52 Cr45.50 Cr-28.44 Cr-7.66 Cr
Investing Cash Flow --5.00 Cr-33.25 Cr23.30 Cr-4.40 Cr
Financing Cash Flow --6.36 Cr-8.27 Cr11.03 L11.92 Cr
Capital Expenditure --5.24 Cr-10.87 Cr-14.86 Cr-29.11 Cr
Free Cash Flow -5.28 Cr34.63 Cr-43.29 Cr-36.77 Cr
Net Change in Cash --84.24 L3.98 Cr-5.02 Cr-13.67 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -63.0%64.4%65.5%64.8%
Operating Margin % -10.7%11.4%-0.8%0.0%
Net Margin % -10.6%20.9%5.0%-0.5%
ROE % -11.6%19.7%4.4%-0.4%
ROCE % -11.3%10.3%-0.7%0.0%

Shareholding Pattern

Insiders
64.04%
Institutions
1.61%
Public Float
4.48%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALBERTDAVD

Google News Sun, 05 Jul 2026

ALBERTDAVD Q2 2026 Earnings: Revenue Declines 3.5% YoY, EPS Turns Negative at ₹-2.62 - SaaS Earnings Trends - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZWUwYVBjTEwwX1Vmdkc4TnR4a1gwTVcxNXdyV004MlZVaHNPdnpsM1VUODJFZHNzLUVJT001d1hVSmxvSmxzUXdscWIxSl9leVpVRHZsak5IRVBBc2d6ZmIxRVJaV1lURGFSRnlNdV9ZQWZOSGE5dzZPX0s5aDQ4M3VJclB3OXliam92Q0…

Google News Fri, 07 Aug 2026

Albert David Share Price Rises 15.77%: Technicals, Valuation - Univest

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE5oLWhuZFZTQkgteE1jLVQ3QVFQbmYtWGdNQW9Lc2RQa0VJeWExYVozR0s1cG9mblMyWjRlTE9pOWRLeERMbFZ1cW9MQzN2YW10bTdDQWlScmp0V2Jnc2lXSUZSN3d4dWc1MkVXVFFldHlPc041SHF0ZWpHSQ?oc=5" target="_blank">A…

Google News ue, 09 Jun 2026

AHCL Stock Price and Chart — NSE:AHCL - TradingView

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1heGxyZ0VuSFZzUW9YYjNsNVVCM2lhSzR4NEJ5YzZncG5WN2F0b0V5UVpETGZWUDJrUmJweHhiaGFjYmhjOEpCRHZONW9HaVV3amY3bXdvWl8?oc=5" target="_blank">AHCL Stock Price and Chart — NSE:AHCL</a>&nbsp;&…

Google News Fri, 29 May 2026

Albert David Limited: Testing Support Levels After Marginal Decline - Dip Buy Trade - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPS0RKVW0zZG5NTVF3Rmg0bGZ6UWswaUktTDEtQlFZNTNtLWxULVluTGRPSFVTcl9TQlFRR1M2WENrR01XRXVlcE1iTFZicmZpeTRKT3Z2U1FlcXFSX25uT3Zva0pOSlRERmZjRHphRGhWOVFSQjl0Z21VOU52WEVWb3VRU19VVTNZMWltUD…

Google News Fri, 07 Aug 2026

Albert David Ltd. Share Price Today: 11.09% Gain Analysed - Univest

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9ZV3lwUkNMZ3VpWDFIWW44WE13cDVIOXhEaFpCWjcxVThHVE1UYWxDWkZGWnlsX2E5bUoyUWRZMWlwdXBJVUpVZE5ialdoVVNqV1dQNmprR2xWSlhBcmttNWc2cEdxMEhPWVFabUx0RVhOV3h1WFlUTg?oc=5" target="_blank">Alber…

Google News Fri, 26 Jun 2026

Albert David Limited (ALBERTDAVD.NS) – Weakening Momentum Below Resistance - Debt Free Companies - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOSThvRThKdGJSRVBBV0t5T1h5R19LUXdiRUFHVjZiUzhHWk1scFJqbFpKNGRjbXByNDJ5VHYxVEd6REtuUk41b0VOY0NXQ2dkc0dmWEd2cUdBZkE1cncydG1EZl9PSDFVQm1NM3Ntdm10U0kzVnI2TDJaMjhpdGxtTnFtSWh3elItMUQzWX…

ALBERTDAVD — Frequently Asked Questions

What is the current share price of Albert David Limited (ALBERTDAVD)?

As of 2026-09-08 04:53 IST, Albert David Limited (ALBERTDAVD) trades at ₹860.25 on NSE. Its 52-week range is ₹582.79 to ₹898.60.

What is the market capitalisation of ALBERTDAVD?

Albert David Limited (ALBERTDAVD) has a market capitalisation of ₹490.96 Cr on NSE.

What is the P/E ratio of ALBERTDAVD?

ALBERTDAVD trades at a trailing price-to-earnings (P/E) ratio of -328.34. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.20.

Does ALBERTDAVD pay a dividend?

Albert David Limited (ALBERTDAVD) currently offers a dividend yield of 0.68%.

What is the return on equity (ROE) of ALBERTDAVD?

ALBERTDAVD has a return on equity (ROE) of -0.38%. Its return on capital employed (ROCE) is 0.76%.

Is ALBERTDAVD a good stock to buy?

This page provides a data-driven analysis of Albert David Limited (ALBERTDAVD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space